Evidence map›Paper›PMID 39475317›Full record

ArticlemSphere2024

Immunomodulatory activity of omadacycline

Madeline Sanders, Paul Beringer

Abstract read
In one paragraph

Article in mSphere, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Efficacy and Safety of Omadacycline in Patients withInfection and drug resistance · 2026
    Article
  3. Antibiotics for Rheumatologic Diseases: A Critical Review.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Madeline SandersAlfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.ORCID 0009-0005-8386-0907
Paul BeringerAlfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-3744-3310

Funding

DOCTORAL AND POST-DOCTORAL TRAINING IN CRANIOFACIAL BIOLOGYT90DE021982 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PAINE, MICHAEL LANSDELL · 2011 to 2025
$6.2M
ENAMEL MATRIX PROTEIN INTERACTIONR01DE013404 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PAINE, MICHAEL LANSDELL · 2000 to 2010
$3.5M
NIDCR NIH HHS R01 DE013404NIDCR NIH HHS T90 DE021982Paratek Pharmaceuticals, Inc.
6 · The paper itself

Abstract

Cystic fibrosis (CF) is characterized by chronic airway obstruction, infection, and inflammation leading to progressive loss of lung function and eventual respiratory failure. Omadacycline, a tetracycline antibiotic, demonstrates

Indexed as

Acute Lung InjuryCytokinesDisease Models, AnimalTetracyclinesAnimalsAnti-Bacterial AgentsAnti-Inflammatory AgentsFemaleHumansImmunologic FactorsLipopolysaccharidesLungMacrophagesMaleMiceMice, Inbred C57BLAnti-Bacterial AgentsAnti-Inflammatory AgentsCytokinesImmunologic FactorsLipopolysaccharidesomadacyclineTetracyclinesacute lung injuryimmunomodulatoryomadacyclinepharmacodynamicspharmacokinetics

Identifiers

PMID39475317
PMCPMC11580420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.